Riskpilot← Back to searchSign inGet full accessGrasp Bioscience AB
ABActiveOrg 5565625810Kärrvägen 35Engineering activities and related technical consultancy · NACE 7112Est. 19980 employees
Revenue 2025
SEK 70K
-64% vs 2024
EBITDA margin
-814.5%
-2493% vs 2024
Equity ratio
83.9%
Financial strength
Net profit 2025
SEK -157K
+1% vs 2024
| Revenue | SEK 70K | -64% |
| EBITDA | SEK -568K | -2493% |
| Net profit | SEK -157K | +1% |
| Total assets | SEK 464K | -29% |
| Equity | SEK 389K | -29% |
| Employees | 0 | — |
Legal name
Grasp Bioscience AB
Org number
5565625810
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
14 november 1998
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsulttjänster inom affärs- och marknadsutveckling inom bioteknik, värdepapperhantering samt bedriva därmed förenlig verksamhet. Bolaget skall även bedriva verksamhet med musik-, TV- och filmproduktion och distribution av musik och media samt därmed förenlig verksamhet.
Address
Kärrvägen 35
Email
carina.schmidt@biobusinesspartners.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 16 | 159 | 1 757 | 251 | 199 | 29 | 195 | 70 |
| Staff expenses | — | — | — | — | — | — | −30 | −27 | −44 | −24 |
| EBITDA | 151 | −138 | −71 | 64 | 1 520 | 183 | −17 | −76 | −22 | −568 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| EBIT | 151 | −138 | −71 | 64 | 1 520 | 183 | −17 | −76 | −22 | −568 |
| Net financials | — | 6 | — | 19 | −65 | −774 | −283 | −27 | −137 | −408 |
| Profit before tax | 112 | −91 | −71 | 147 | 1 146 | −204 | −85 | 42 | −159 | −157 |
| Tax | −26 | −0 | −0 | −0 | −234 | −40 | −43 | −18 | — | — |
| Net profit | 86 | −91 | −71 | 147 | 912 | −244 | −129 | 24 | −159 | −157 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 861 | 536 | 483 | 670 | 2 226 | 1 680 | 983 | 775 | 656 | 464 |
| Equity | 733 | 442 | 371 | 518 | 1 430 | 935 | 707 | 706 | 547 | 389 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — |
| Short-term debt | 87 | 94 | 112 | 152 | 436 | 385 | 132 | 70 | 110 | 75 |
| Total debt | 87 | 94 | 112 | 152 | 436 | 385 | 132 | 70 | 110 | 75 |
EBITDA margin
-814.5%
This company
15.8%
Market median
-5255% vs market
20162025
Equity ratio
83.9%
This company
38.2%
Market median
+120% vs market
20162025
Return on equity
-40.4%
This company
18.4%
Market median
-320% vs market
20162025
Net profit margin
-225.7%
This company
8.1%
Market median
-2886% vs market
20162025
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20162025
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Grasp Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Carina Schmidt | Chief Executive Officer | 0 companies |
| Hans Jacob Nilsen | Deputy Board Member | 0 companies |